Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.00M | 985.80K | 850.10K | 822.20K | 780.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.97M | 2.60M | 3.23M | 3.55M | 3.67M |
| Operating Income | -2.97M | -2.60M | -3.23M | -3.55M | -3.67M |
| Income Before Tax | -2.75M | -2.29M | -3.01M | -3.31M | -3.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.75 | -2.29 | -3.01 | -3.31 | -3.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.75M | -2.29M | -3.01M | -3.31M | -3.48M |
| EBIT | -2.97M | -2.60M | -3.23M | -3.55M | -3.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.06 | -0.05 | -0.07 | -0.08 | -0.09 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.04 | -0.05 | -0.05 |
| EPS Diluted | -0.06 | -0.05 | -0.07 | -0.08 | -0.09 |
| Normalized Diluted EPS | -0.04 | -0.03 | -0.04 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 182.78M | 181.44M | 175.62M | 168.98M | 162.34M |
| Average Diluted Shares Outstanding | 182.78M | 181.44M | 175.62M | 168.98M | 162.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |